Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
Gastroenterology2015Vol. 149(7), pp. 1775–1783.e2
Citations Over TimeTop 10% of 2015 papers
Naoki Yoshimura, Mamoru Watanabe, Satoshi Motoya, Keiichi Tominaga, Katsuyoshi Matsuoka, Ryuichi Iwakiri, Kenji Watanabe, Toshifumi Hibi∥
Abstract
AJM300 was well tolerated and more effective than placebo in inducing clinical response, clinical remission, and mucosal healing in patients with moderately active UC. ClinicalTrials.jp no: JapicCTI-132293.
Related Papers
- THE EXPERIMENTAL STUDY OF THE RELATED CYTOKINES FOR IN PATIENTS WITH ULCERATIVE COLITIS.(2005)
- → Μελέτη της πολυπαραγοντικής αναλγησίας στο μετεγχειρητικό πόνο μετά από λαπαροσκοπική χολοκυστεκτομή(2014)
- Investigation of Serum NO Levels in Patients With Ulcerative Colitis(2002)
- Determination of plasma P-selection in patients with ulcerative colitis and their clinical significance(2004)
- The severity correlation of TNF-α,IL-6 and IL-8 levels in plasma in patients with ulcerative colitis and their clinical significances(2008)